Plasma Protease C1-inhibitor Treatment Market
- 2026 年市場規模
- USD 4.38 Bn
- 2033 年預估規模
- USD 8.06 Bn
- 年複合成長率 CAGR
- 9.1%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Plasma Protease C1-inhibitor Treatment Market, By Drug Type (C1-inhibitors, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist), By Dosage (Lyophilized, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
報告摘要
C1-inhibitor (C1-H) belongs to the superfamily of serine protease inhibitors. C1-inhibitors controls the activation of the C1 complex. It forms a proteolytically inactive stoichiometric complex with the C1r or C1s proteases. It also plays an important role in regulating important physiological pathways including complement activation, blood coagulation, fibrinolysis, and generation of kinins. It is the most efficient inhibitor of FXIIa factors and also inhibits chymotrypsin and kallikrein.
Market Dynamics
Hereditary angioedema (HAE) is the disease condition characterized by the C1 esterase inhibitor deficiency. According to reported data by National Center for Biotechnology Information in 2013, the estimated prevalence of HAE in the general population is between 1 in 10,000 and 1 in 150,000 individuals worldwide. Cinryze, a pharmaceutical-grade C1-inhibitor, was approved by U.S.FDA for the treatment of HAE in 2008. Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 esterase inhibitor product; it has been approved for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE. Thus, the increasing trend of using plasma-derived C1 esterase inhibitor products in HAE treatment is expected to drive growth of the global plasma protease C1-inhibitor treatment market.
Key features of the study
• This report provides in-depth analysis of the global plasma protease C1-inhibitor treatment market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global plasma protease C1-inhibitor treatment market based on the following parameters – company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key players operating in the global plasma protease C1-inhibitor treatment market include CSL Behring LLC, Takeda Pharmaceutical Company Limited, Ionis Pharmaceuticals, Inc., Pharming Technologies B.V., Centogene AG, BioCryst Pharmaceuticals, and KalVista Pharmaceuticals, Inc.
• Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
• The global plasma protease C1-inhibitor treatment market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global plasma protease C1-inhibitor treatment market.
Plasma Protease C1-inhibitor Treatment Market Segmentation
• By Drug Type (Revenue, USD Bn, 2021-2033)
o C1-inhibitors
o Kallikrein Inhibitor
o Selective Bradykinin B2 Receptor Antagonist
• By Dosage (Revenue, USD Bn, 2021-2033)
o Lyophilized
o Injectable
• By Distribution Channel (Revenue, USD Bn, 2021-2033)
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• Global Plasma Protease C1-inhibitor Treatment Market, By Region (Revenue, USD Bn, 2021-2033)
o North America
U.S.
Canada
o Latin America
Brazil
Mexico
Argentina
Rest of Latin America
o Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC
Israel
Rest of Middle East
o Africa
South Africa
Central Africa
North Africa
• Key Players
o CSL Behring LLC
o Takeda Pharmaceutical Company Limited
o Ionis Pharmaceuticals, Inc.
o Pharming Technologies B.V.
o Centogene AG
o BioCryst Pharmaceuticals
o KalVista Pharmaceuticals, Inc.
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snapshot, By Drug Type
Market Snapshot, By Dosage
Market Snapshot, By Distribution Channel
Market Snapshot, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Impact Analysis
o Market Trends
o Key Developments
o Product Approval
o Collaboration/Merge/Acquisition
o Regulatory Landscape
o PEST Analysis
o Porter’s Five Forces Analysis
o Epidemiology
o Robust Pipeline Analysis
4. Global Plasma Protease C1-inhibitor Treatment Market, By Drug Type, 2021 – 2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022– 2033
Segment Trends
o C1-inhibitors
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
o Kallikrein Inhibitor
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
o Selective Bradykinin B2 Receptor Antagonist
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
5. Global Plasma Protease C1-inhibitor Treatment Market, By Dosage, 2021 – 2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Lyophilized
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
o Injectable
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
6. Global Plasma Protease C1-inhibitor Treatment Market, By Distribution Channel, 2021 – 2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
o Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
o Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
7. Global Plasma Protease C1-inhibitor Treatment Market, By Region, 2021 – 2033, (USD Bn)
o Introduction
Market Share Analysis, By Region, 2026 and 2033 (%)
Y-o-Y Growth Analysis, For Regions, 2022–2033
Regional Trends
o North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Bn)
o U.S.
o Canada
o Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Bn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Bn)
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Bn)
o China
o India
o Japan
o ASEAN
o Australia
o South Korea
o Rest of Asia Pacific
o Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Bn)
o GCC
o Israel
o Rest of Middle East
o Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 – 2033, (USD Bn)
o North Africa
o Central Africa
o South Africa
8. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
o Company Profile
CSL Behring LLC
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Takeda Pharmaceutical Company Limited
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Ionis Pharmaceuticals, Inc
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Pharming Technologies B.V.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Centogene AG
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
BioCryst Pharmaceuticals
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
KalVista Pharmaceuticals Inc
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
o Analyst Views
9. Section
o References
o Research Methodology
o About Us
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們